Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells

Fei Shen, Xinjian Xue, George Weber

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Propose. Tamoxifen and genistein were tested for synergism in estrogen receptor- negative human breast carcinoma MDA-MB-435 cells because the two compounds decrease signal transduction activity through different biochemical mechanisms and arrest the cell cycle at different phases. Materials and Methods. The combination effect of tamoxifen and genistein on signal transduction was determined by measuring IP3 concentrations and on cell proliferation and colony formation by growth inhibition assay and clonogenic assay. Results. In growth inhibition assays, for tamoxifen and genistein in the carcinoma cells the IC50s were (mean ± SE) 17 ± 0.9 and 27 ± 1.6 μM; in clonogenic assays the LC50s were 0.9 ± 0.4 and 12.5 ± 1.1 μM, respectively. When tamoxifen and genistein were simultaneously added to the cells, synergism was observed in growth inhibition, in cytotoxicity and in the reduction of inositol 1,4,5-triphosphate concentration. Conclusion. The synergistic down-regulation of signal transduction by tamoxifen and genistein may explain, in part at least, the synergistic antiproliferative and cytotoxic actions of the two compounds. The synergism of tamoxifen and genistein may be of interest in the clinical treatment of breast carcinoma.

Original languageEnglish
Pages (from-to)1657-1662
Number of pages6
JournalAnticancer Research
Volume19
Issue number3 A
StatePublished - 1999

Fingerprint

Genistein
Tamoxifen
Estrogen Receptors
Signal Transduction
Down-Regulation
Breast Neoplasms
Growth
Inositol 1,4,5-Trisphosphate
Cell Cycle Checkpoints
Cell Proliferation
Carcinoma

Keywords

  • Genistein
  • Human breast carcinoma cells
  • Inositol 1,4,5-trisphosphate
  • Signal transduction
  • Synergistic down-regulation
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. / Shen, Fei; Xue, Xinjian; Weber, George.

In: Anticancer Research, Vol. 19, No. 3 A, 1999, p. 1657-1662.

Research output: Contribution to journalArticle

@article{5c07d62e12c148a5ad0a51bd3c83f8d3,
title = "Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells",
abstract = "Propose. Tamoxifen and genistein were tested for synergism in estrogen receptor- negative human breast carcinoma MDA-MB-435 cells because the two compounds decrease signal transduction activity through different biochemical mechanisms and arrest the cell cycle at different phases. Materials and Methods. The combination effect of tamoxifen and genistein on signal transduction was determined by measuring IP3 concentrations and on cell proliferation and colony formation by growth inhibition assay and clonogenic assay. Results. In growth inhibition assays, for tamoxifen and genistein in the carcinoma cells the IC50s were (mean ± SE) 17 ± 0.9 and 27 ± 1.6 μM; in clonogenic assays the LC50s were 0.9 ± 0.4 and 12.5 ± 1.1 μM, respectively. When tamoxifen and genistein were simultaneously added to the cells, synergism was observed in growth inhibition, in cytotoxicity and in the reduction of inositol 1,4,5-triphosphate concentration. Conclusion. The synergistic down-regulation of signal transduction by tamoxifen and genistein may explain, in part at least, the synergistic antiproliferative and cytotoxic actions of the two compounds. The synergism of tamoxifen and genistein may be of interest in the clinical treatment of breast carcinoma.",
keywords = "Genistein, Human breast carcinoma cells, Inositol 1,4,5-trisphosphate, Signal transduction, Synergistic down-regulation, Tamoxifen",
author = "Fei Shen and Xinjian Xue and George Weber",
year = "1999",
language = "English",
volume = "19",
pages = "1657--1662",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells

AU - Shen, Fei

AU - Xue, Xinjian

AU - Weber, George

PY - 1999

Y1 - 1999

N2 - Propose. Tamoxifen and genistein were tested for synergism in estrogen receptor- negative human breast carcinoma MDA-MB-435 cells because the two compounds decrease signal transduction activity through different biochemical mechanisms and arrest the cell cycle at different phases. Materials and Methods. The combination effect of tamoxifen and genistein on signal transduction was determined by measuring IP3 concentrations and on cell proliferation and colony formation by growth inhibition assay and clonogenic assay. Results. In growth inhibition assays, for tamoxifen and genistein in the carcinoma cells the IC50s were (mean ± SE) 17 ± 0.9 and 27 ± 1.6 μM; in clonogenic assays the LC50s were 0.9 ± 0.4 and 12.5 ± 1.1 μM, respectively. When tamoxifen and genistein were simultaneously added to the cells, synergism was observed in growth inhibition, in cytotoxicity and in the reduction of inositol 1,4,5-triphosphate concentration. Conclusion. The synergistic down-regulation of signal transduction by tamoxifen and genistein may explain, in part at least, the synergistic antiproliferative and cytotoxic actions of the two compounds. The synergism of tamoxifen and genistein may be of interest in the clinical treatment of breast carcinoma.

AB - Propose. Tamoxifen and genistein were tested for synergism in estrogen receptor- negative human breast carcinoma MDA-MB-435 cells because the two compounds decrease signal transduction activity through different biochemical mechanisms and arrest the cell cycle at different phases. Materials and Methods. The combination effect of tamoxifen and genistein on signal transduction was determined by measuring IP3 concentrations and on cell proliferation and colony formation by growth inhibition assay and clonogenic assay. Results. In growth inhibition assays, for tamoxifen and genistein in the carcinoma cells the IC50s were (mean ± SE) 17 ± 0.9 and 27 ± 1.6 μM; in clonogenic assays the LC50s were 0.9 ± 0.4 and 12.5 ± 1.1 μM, respectively. When tamoxifen and genistein were simultaneously added to the cells, synergism was observed in growth inhibition, in cytotoxicity and in the reduction of inositol 1,4,5-triphosphate concentration. Conclusion. The synergistic down-regulation of signal transduction by tamoxifen and genistein may explain, in part at least, the synergistic antiproliferative and cytotoxic actions of the two compounds. The synergism of tamoxifen and genistein may be of interest in the clinical treatment of breast carcinoma.

KW - Genistein

KW - Human breast carcinoma cells

KW - Inositol 1,4,5-trisphosphate

KW - Signal transduction

KW - Synergistic down-regulation

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0032781422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032781422&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 1657

EP - 1662

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -